Assembly Biosciences Inc (NASDAQ:ASMB)’s share price was up 8.4% during trading on Friday . The company traded as high as $52.37 and last traded at $49.91. Approximately 818,000 shares were traded during mid-day trading, an increase of 807% from the average daily volume of 90,155 shares. The stock had previously closed at $46.05.

A number of equities analysts have recently commented on ASMB shares. BidaskClub upgraded Assembly Biosciences from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. Jefferies Group initiated coverage on Assembly Biosciences in a research note on Wednesday, November 8th. They issued a “buy” rating and a $50.00 price objective on the stock. Zacks Investment Research lowered Assembly Biosciences from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Finally, Chardan Capital restated a “buy” rating on shares of Assembly Biosciences in a research note on Sunday, September 17th.

In related news, Director William R. Ringo sold 1,000 shares of the business’s stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $33.70, for a total transaction of $33,700.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Insiders own 19.60% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Parametric Portfolio Associates LLC bought a new stake in shares of Assembly Biosciences in the 1st quarter valued at approximately $226,000. Vanguard Group Inc. grew its stake in shares of Assembly Biosciences by 11.2% in the 1st quarter. Vanguard Group Inc. now owns 503,851 shares of the biopharmaceutical company’s stock valued at $12,843,000 after purchasing an additional 50,615 shares during the period. Geode Capital Management LLC grew its stake in shares of Assembly Biosciences by 32.3% in the 1st quarter. Geode Capital Management LLC now owns 97,964 shares of the biopharmaceutical company’s stock valued at $2,497,000 after purchasing an additional 23,926 shares during the period. Renaissance Technologies LLC bought a new stake in shares of Assembly Biosciences in the 1st quarter valued at approximately $242,000. Finally, Goldman Sachs Group Inc. bought a new stake in shares of Assembly Biosciences in the 1st quarter valued at approximately $1,570,000. Hedge funds and other institutional investors own 61.88% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.dailypolitical.com/2017/12/01/assembly-biosciences-asmb-trading-up-8-4.html.

About Assembly Biosciences

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

Receive News & Ratings for Assembly Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.